VBL Therapeutics

209 articles about VBL Therapeutics

• VBL Therapeutics To Present Company Overview At Upcoming Conferences In March

  3/4/2015

• VBL Therapeutics Reports Topline Results From Phase 2 Studies Of VB-201 In Psoriasis And Ulcerative Colitis

  2/17/2015

• VBL Therapeutics Announces Removal Of FDA Partial Clinical Hold On VB-111

  2/17/2015

• VBL Therapeutics To Present Preclinical Data At Keystone Symposium On Liver Metabolism And Nonalcoholic Fatty Liver Disease

  2/9/2015

• VBL Therapeutics Receives European Patent Issuance On Lecinoxoid Platform Technology

  2/6/2015

• VBL Therapeutics Announces Ron Cohen And Philip Serlin Nominated To Board Of Directors

  1/20/2015

• VBL Therapeutics Announces Positive Phase 2a Data For VB-111 In Recurrent Thyroid Cancer

  12/22/2014

• VBL Therapeutics Announces Last Patient Out In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis

  12/15/2014

• VBL Therapeutics To Present Company Overview At Upcoming Conferences

  11/25/2014

• VBL Therapeutics To Present Interim Phase 2 Data From VB-111 In Recurrent Glioblastoma At 19th Annual Scientific Meeting Of The Society For Neuro-Oncology (SNO)

  11/13/2014

• VBL Therapeutics Announces Third Quarter 2014 Financial Results

  11/13/2014

• VBL Therapeutics To Report Third Quarter 2014 Financial Results On November 13, 2014

  11/3/2014

• VBL Therapeutics To Present Interim Phase 2 Data From VB-111 In Recurrent Glioblastoma At 19th Annual Scientific Meeting Of The Society For Neuro-Oncology (SNO)

  11/3/2014

• VBL Therapeutics Announces Closing Of Initial Public Offering

  10/7/2014

• VBL Therapeutics Announces Pricing Of Initial Public Offering

  10/1/2014

• Israel's VBL Therapeutics Terminates NASDAQ IPO Due To Shareholder Mishap

  8/12/2014

• VBL Therapeutics Announces Pricing Of Initial Public Offering

  7/31/2014

• VBL Therapeutics Announces Completion Of Enrollment In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis

  6/20/2014

• VBL Therapeutics Announces Novel Mechanistic Data For VB-201 – A First In Class Orally Available Anti-Inflammatory Compound That Inhibits CD14-TLR4 And TLR2-Dependent Innate Cell Activation

  12/6/2013

• VBL Therapeutics Receives FDA Fast Track Designation For Lead Compound VB-111

  11/27/2013